Magic mushroom compound tested for OCD in small trial

NCT ID NCT05370911

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study is testing whether repeated doses of psilocybin, the active ingredient in magic mushrooms, can reduce symptoms of obsessive-compulsive disorder (OCD). Twenty-eight adults with moderate-to-severe OCD who have not responded to standard treatments will receive two doses of psilocybin. The study uses a waitlist control group and measures changes in OCD severity using a standard rating scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
psilocybin (synthetic magic mushroom ingredient)
What this could lead to
If it works, this could point toward a new treatment option for people with obsessive-compulsive disorder who haven't found relief from standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 28 participants, so results may not apply to everyone. Psilocybin can cause intense psychological effects and is not yet proven safe or effective for OCD.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSESSIVE - COMPULSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Enact Research Collaborative (40 Temple St, 4th Floor)

    New Haven, Connecticut, 06510, United States

  • Yale Program for Psychedelic Research

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.